anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Up-regulation of SST2 in activated macrophages represents a novel imaging target for measuring vascular inflammation, which has been previously examined in atherosclerosis using 68Ga-DOTATATE. To test the hypothesis that SST2 PET imaging can accurately identify LVV, patients with active GCA or Takayasu arteritis will undergo vascular 68Ga-DOTATATE or 18F-fluoroethyltriazole-(Tyr3)-octreotate (FETO) PET-MRI at baseline, with repeat imaging after 6 months of treatment. A group of individuals with LVV in clinical remission will also undergo SST2 PET imaging. Data from patients with clinically inactive disease will serve to confirm tracer specificity for active disease, as well as signal reproducibility. 18F-FETO is an alternative SST2 tracer to 68Ga-DOTATATE; the longer half-life and shorter positron range of 18F compared to 68Ga may offer several advantages, including wider tracer availability and improved spatial resolution when imaging small arteries. All patients will also undergo 18F-FDG imaging before treatment, where clinically indicated.
The invention discloses a comprehensive utilization method for a sea cucumber processing waste liquid. The comprehensive utilization method comprises the following steps: S1. concentrating the sea cucumber processing waste liquid, adding ethanol and carrying out ethanol precipitation, thus obtaining an ethanol precipitation freeze-dried powder and a supernatant; S2. uniformly mixing the ethanol precipitation freeze-dried powder with absolute ethanol and n-hexane or the mixed organic solvent of the absolute ethanol and the n-hexane in a ratio of 1:(5 to 15), and standing for 8-24h; precipitating and vaporizing the solvent to obtain a degreased powder; S3. adding water in the degreased powder, removing water-soluble impurities, then centrifugally separating and precipitating to obtain a sea cucumber protein polysaccharide powder; S4. recovering the solvent from the supernatant obtained in the step S1 at a reduced pressure, and adsorbing the residual liquid by weak-polar macroporous adsorption resin; eluting by water until the eluent is colourless, and then eluting by ethanol solution with three concentrations; collecting the ethanol eluent, recovering the solvent, thus obtaining sea cucumber saponin products with two purities. According to the method disclosed by the invention, the sea cucumber protein polysaccharide powder and the sea cucumber saponin products are simply and efficiently produced by the sea cucumber processing waste liquid; the method has the characteristics of being low in cost, high in yield, and high in quality.
Participants will receive 3 weekly treatment sessions of 3 hours each, for a period of 4 weeks and a total of 12 sessions. In the first two hours of treatment, an experienced physiotherapist will propose a programme based on stretching exercises, muscle strengthening and educational interventions. During the last hour of treatment, subjects allocated to this group will receive gait rehabilitation on the Lokomat device (Hocoma). . In this case the parameters for setting the machine will be determined by the physiotherapist in charge for treatment administration in relation to the specific characteristics of the patient.
Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
The recommended starting dose is 1,000 mg taken as a single dose with or without food. Some patients may obtain more symptomatic relief from 1,500 mg to 2,000 mg per day. Nabumetone tablets can be given in either asingl or twice-daily dose. Dosages greater than 2,000 mg per day have not been studied. The lowest effective dose should be used for chronic treatment (see WARNINGS: Renal Effects: ). Patients weighing under 50 kg may be less likely to require dosages beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients' requirements. 

### HOW SUPPLIED

750 mg-Beige colored, film-coated, oval-shaped biconvex tablets debossed with IG on one side and 258 on the other are supplied in bottles of 30 (NDC 70934-347-30).

Store at 20° to 25°C (68° to 77 oF) [See USP Controlled Room Temperature]. 

Dispense in tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Rev. 08/15
Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system (CNS). MS is categorized into several distinct forms according to clinical symptoms and medical examinations. Relapsing-remitting multiple sclerosis (RRMS) is characterized by attacks of worsening neurologic function, followed by partial or complete recovery periods. Patients can also present a gradual but steady progression of the disease (progressive forms). While several treatment options are currently available, no treatment completely stops the disease progression. Therefore, a deeper understanding regarding the mechanism of the disease development is essential to generate more efficient treatment strategies. CD4 T cells are known to be significantly involved in the formation of the CNS lesions characteristic of MS.The investigators hypothesize that different types of B and CD4 T cells play major roles in different forms of the disease. They will determine the phenotype and functions of the cells from the immune system particularly B and CD4 T cells present in the blood and cerebro-spinal fluid (CSF) of patients diagnosed with multiple sclerosis or presenting a clinically isolated syndrome.

The study will recruit 150 patients followed in Bordeaux University Hospital and diagnosed for clinically isolated syndrome (CIS) or multiple sclerosis (MS). Blood and CSF will be collected during a scheduled visit to study the properties of cells from the immune system in particular CD4 T cells in multiple sclerosis. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with the properties of blood and CSF lymphocytes. No extra visit will be needed and the blood and CSF samples will be collected at the same times as those collected for clinical purposes.
The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was \>3.
PURPOSE: A composition containing 3-methyladenine is provided to decompose neutral lipid into glycerol and free fatty acid and to prevent or treat obesity, diabetes, and hyperlipidemia. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains 3-methyladenien as an active ingredient. 3-methyladenine decomposes neutral lipid into glycerol and free fatty acid. A food composition for preventing or treating obesity contains 3-methyladenine as an active ingredient. The composition is used for preventing or treating obesity-associated metabolic diseases including diabetes, arteriosclerosis, metabolic diseases, and hyperlipidemia. The pharmaceutical composition is manufactured in the form of a liquid formulation or parenteral formulation.
The invention discloses a medicinal herb health care pillow, relating to a health care pillow. According to the invention, the pillow is internally provided with a medicinal herb bag; and bulk pharmaceutical materials in the medicinal herb bag comprise the following components by weight: 50-150g of wild chrysanthemum flower, 20-80g of polygala tenuifolia, 20-80g of vine of multiflower knotweed, 20-80g of selfheal spike, 15-55g of notopterygium root, 15-55g of radix angelicae pubescentis, 10-50g of angelica root, 10-50g of gastrodia elata, 5-15g of camphor and 5-15g of borneol. The preparation method of the medicinal herb health care pillow comprises the following steps of: firstly smashing the bulk pharmaceutical materials into particles with the particle size of less than 3mm; mixing the bulk pharmaceutical material particles, packaging the mixture into a packaging bag to form the medicinal herb bag; and respectively arranging a protective layer on the bottom layer and the upper layer of the medicinal herb bag, wherein the protective layers are made of air permeable materials. The invention has the beneficial effect that the medicinal herb health care pillow is mainly used for treatment or adjuvant treatment of diseases such as neurasthenia, hyposomnia, headache and the like. By adopting the pillow, diseases can be treated unknowingly during sleep necessary for people. After the pillow is used for a long time, people can effectively absorb ingredients in a long-actuating manner during sleep, and no oral administration or external moxibustion is required, thus the aims of clearing and activating the channels and collaterals, regulating vital energy and calming the nerves, keeping fit and being far from diseases are achieved.
Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
Provided in the present invention is a method for purifying a pemetrexed intermediate. The method comprises the following steps: A) dissolving a crude product, a pemetrexed intermediate, in a solvent to obtain a pemetrexed intermediate crude product solution; and B) mixing the pemetrexed intermediate crude product solution with trifluoroacetic acid to obtain a trifluoroacetate of the pemetrexed intermediate. In the present invention, by adding an appropriate acid under a certain solvent and temperature to form a salt with the intermediate, the aim of purifying the pemetrexed intermediate can be achieved, the content of impurities in the intermediate can be reduced, and a high-purity pemetrexed intermediate can be obtained. Use of the intermediate for preparing a pemetrexed disodium raw material medicine can effectively reduce impurity residues in the raw material medicine, thereby obtaining a high-purity pemetrexed disodium raw material medicine that meets medicine standards. The preparation method provided in the present invention is simple to operate and suitable for industrial production. In addition, the trifluoroacetic acid used does not introduce any genotoxic impurity, resulting in higher safety.
The efficacy of RAZADYNE® ER Extended-Release Capsules was studied in a randomized, double-blind, placebo-controlled trial which was 6 months in duration, and had an initial 4-week dose-escalation phase. In this trial, patients were assigned to one of 3 treatment groups: RAZADYNE® ER in a flexible dose of 16 to 24 mg once daily; RAZADYNE® Tablets in a flexible dose of 8 to 12 mg twice daily; and placebo. The primary efficacy measures in this study were the ADAS-cog and CIBIC-plus. On the protocol-specified primary efficacy analysis at Month 6, a statistically significant improvement favoring RAZADYNE® ER over placebo was seen for the ADAS-cog, but not for the CIBIC-plus. RAZADYNE® ER showed a statistically significant improvement when compared with placebo on the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, a measure of function, and a secondary efficacy measure in this study. The effects of both RAZADYNE® ER Capsules and RAZADYNE® Tablets on the ADAS-cog, CIBIC-plus, and ADCS-ADL were similar in this study.
High-intensity exercise of inspiratory muscle was able to reduce glucose levels in previous studies, but the mechanisms underlying this reduction remain largely unknown. The present study will investigate this phenomenon, and whether confirmed, the inspiratory muscle loading would be a new approach for lowering glucose levels and glucose variability in type 2 diabetes.

The subjects with type 2 diabetes will be recruited from the ambulatory of the Hospital de Clinicas de Porto Alegre. The patients will be randomized to inspiratory muscle exercise with a high intensity load (MIP 60%) or to exercise with a load placebo (MIP 2%), on two different days. The subjects will come in the laboratory for three days consecutively during 2 weeks. On the first day will be placed the CGMS device. On the second day will be the controlled ventilation protocol with subsequently inspiratory muscle exercise, using 2% or 60% of MIP as randomized a priori. On the third day the CGMS will be removed. Individuals who are using beta-blockers will be advised to withdraw the medication 24 hours before the protocols. During all protocols will be recorded the continuous blood pressure to assess heart rate and blood pressure variabilities, both time and frequency domains will be analyzed. Also, the calf blood flow, inspiratory pressure, end-tidal carbon dioxide and oxygen saturation will be taking.
In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
Our research team retrospectively analyzes biomarkers that distinguish accommodation and acute antibody-mediated rejection through transcriptomic analysis of peripheral blood in patients with ABO blood type incompatibility kidney transplantation at Seoul National University Hospital. Through this, a classification model was developed to distinguish accommodation and antibody-mediated rejection using peripheral blood marker at the time of the protocol biopsy on the 10th day after renal transplantation, and recently reported as a new peripheral blood marker-based molecular diagnostic method. On the 10th day after surgery, transcriptomic analysis through RNA-seq was performed using samples of peripheral blood from 18 patients with accommodation and 10 patients with antibody-mediated rejection confirmed by protocol biopsy. The candidate genes were validated in the discovery set and another independent training set through quantitative real-time polymerase chain reaction (PCR). Finally, a 5-gene classification model including COX7A2L, CD69, CD14, CFD, and FOXJ3 was developed through logistic regression analysis.

To evaluate the diagnostic effectiveness (sensitivity, specificity) for the peripheral blood marker-based molecular diagnostic method by prospectively recruiting patients with ABO blood type incompatible kidney transplantation is needed. And, it is necessary to evaluate the effectiveness of whether the peripheral blood marker-based molecular diagnostic method can predict antibody-mediated rejection or accommodation as a result of protocol biopsy that will be performed on the 10th day after transplantation - peripheral blood samples collected earlier than the 10th day (day 5 and day 7) after ABO blood type incompatible kidney transplantation.
Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation.
AIM: To evaluate the clinical and pathological features and prognosis of idiopathic membranous nephropathy (IMN) with focal segmental sclerosis (FSGS) in a group of Russian patients.
MATERIALS AND METHODS: 101 patients with morphologically verified IMN were enrolled in our single-center cohort retrospective study. The patients were divided into IMN group and IMN+FSGS group. The primary and secondary outcomes were analyzed in 59 patients, which had follow-up data for period more than 6 months.
RESULTS: At the time of renal biopsy the median age was 46.0 (33.0; 55.0) years and the median follow-up was 6.8 (4.0; 15.6) months. Secondary FSGS was revealed in 15 (14.9%) patients with IMN. The IMN and IMN+FSGS groups did not differ in gender, age of onset IMN and age of renal biopsy. In the IMN+FSGS group proteinuria was higher and estimated glomerular filtration rate was lower than that in the IMN group (p<0.05). The systolic arterial pressure and creatinine levels in the IMN+FSGS group were slightly higher than in the IMN group, but the difference was not significant. Anti-PLA2R positivity was similar in both groups. Chronic kidney disease (CKD) progression was observed in 10/52 (19.2%) and 5/7 (71.4%) patients in IMN and IMN+FSGS groups, respectively. In a multivariate Cox regression model, age of renal biopsy (odds ratio - OR 1.12, 95% confidence interval - CI 1.03-1.22; р=0.07), FSGS (OR 0.05, 95% CI 0.01-0.34; р=0.002) и response to initial course of immunosuppression (OR 0.33, 95% CI 0.12-0.95; р=0.039) were associated with the CKD progression.
CONCLUSION: In patients with IMN secondary FSGS is associated with a greater severity of proteinuria and a decrease in estimated glomerular filtration rate, and is also an independent factor of the CKD progression.
The invention relates to the field of medicine, namely to allergology and can be used for obtaining purified from nutrient medium biomass of microscopic Dermatophagoides farinae mites, applied for obtaining allergen. The method for purification consists in cultivation of Dermatophagoides farinae mites on powder of Daphnia. Growing was carried out in closed 500 ml beakers. Cultivation is carried out until complete exhaustion of nutrient medium with the following transfer of the entire mite mass into the next beaker without nutrient medium for a week. The procedure is repeated 4 times (4 weeks). The disclosed method was applied at the laboratory for production of allergen from Dermatophagoides farinae mites and can be used for purification of mite biomass in order to obtain initial biomaterial without admixtures of nutrient medium.
Participants will receive 1 of 3 dose levels of romosozumab. All participants also received calcium and vitamin D.
The hypocholesterolemic effect of ezetimibe was evaluated in cholesterol-fed Rhesus monkeys, dogs, rats, and mouse models of human cholesterol metabolism. Ezetimibe was found to have an ED50 value of 0.5 mcg/kg/day for inhibiting the rise in plasma cholesterol levels in monkeys. The ED50 values in dogs, rats, and mice were 7, 30, and 700 mcg/kg/day, respectively. These results are consistent with Ezetimibe being a potent cholesterol absorption inhibitor.

In a rat model, where the glucuronide metabolite of ezetimibe (SCH 60663) was administered intraduodenally, the metabolite was as potent as the parent compound (SCH 58235) in inhibiting the absorption of cholesterol, suggesting that the glucuronide metabolite had activity similar to the parent drug.

In 1-month studies in dogs given ezetimibe (0.03 to 300 mg/kg/day), the concentration of cholesterol in gallbladder bile increased ~2- to 4-fold. However, a dose of 300 mg/kg/day administered to dogs for one year did not result in gallstone formation or any other adverse hepatobiliary effects. In a 14-day study in mice given ezetimibe (0.3 to 5 mg/kg/day) and fed a low-fat or cholesterol-rich diet, the concentration of cholesterol in gallbladder bile was either unaffected or reduced to normal levels, respectively.

A series of acute preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of 14C-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or the fat-soluble vitamins A and D.

In 4- to 12-week toxicity studies in mice, ezetimibe did not induce cytochrome P450 drug metabolizing enzymes. In toxicity studies, a pharmacokinetic interaction of ezetimibe with statins (parents or their active hydroxy acid metabolites) was seen in rats, dogs, and rabbits.
Lateral ankle sprains are one of the most common injuries sustained by the general population with the greatest rates in people who are physically active or service members. Approximately 40% of lateral ankle sprain patients develop chronic ankle instability (CAI) characterized by recurrent lateral ankle sprains, repetitive sensations of ankle "giving way", residual ankle sprain symptoms, and self-reported disability. Factors related to the development and progression of CAI has been thoroughly studied. However, few interventions have been developed which have successfully created long term reductions in re-injury rates, physical function, or health-related quality of life. Recent work by our research team has uncovered several novel motor and sensory deficits in the foot in patients with CAI. Deficits in foot function may contribute to the high re-injury rates, deficits in balance and strength, and diminished health-related quality of life commonly experienced by individuals with CAI. The investigators expect the additive effect of FIRE with components of the standard of care (balance training, strength training, and range of motion) will create the synergy needed to reduce future injuries (Aim 1), enhance physical function (Aim 2), and reduce self-reported disability in CAI patients (Aim 3).
The invention discloses a preparation method a traditional Chinese medicine wine capable of keeping young and dispersing pathogenic wind and dampness. The wine is prepared from 60g of argil (half of fired and half of calcined), 30g of gypsum, 30g of reddle, 30g of Hengshan, 30g of Sichuan pepper, 30g of polygala root, 30g of Hendu, 30g of tuber pinellia (washed), 30g of mirabilite, 30g of figwort, 30g of ephedra, 30g of radix sileris, 30g of balloonflower, 30g of dried radix rehmanniae, 30g of Gentiana macrophylla, 30g of photinia leaf, 30g of herba pyrrosiae, 30g of coptis, 30g of shikimmi, 30g of swimming stone, 30g of dodder, 30g of honey-fried licorice root, 45g of crystobalite, 20 peeled almonds, 1500g of distillery yeast and 3000g of glutinous rice. The preparation method comprises the following steps: preparing the first 24 components into crude powder, and adding into a cloth bag for later use; cleaning the glutinous rice, draining, steaming, cooling, adding the distillery yeast, uniformly stirring, adding into a jar, sealing, keeping the temperature, adding the medicine bag into the wine after the wine is mature, sealing, immersing for 7-10 days, and filtering to remove slag; or putting the medicine bag in a container, adding 5000ml of white wine, sealing, immersing for 7-10 days, and filtering to remove slag. The wine has the effects of eliminating the pathogenic factor, moisturizing the skin, improving the facial color and retaining youthful looks. The wine is mainly used for treating weak constitution, sense of pathogenic wind and dampness, soreness of the waist, weakness of limbs, colorless face and other symptoms. The wine is orally taken 10-15ml a time, twice a day.